Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Preiss, D, Tobert, JA, Hovingh, GK, Reith, C
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Elsevier 2020

Antzeko izenburuak

Lipid-modifying agents, from statins to PCSK9 inhibitors
nork: Preiss, D, et al.
Argitaratua: (2020)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
nork: Sanjiv Gupta
Argitaratua: (2015-09-01)

United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
nork: Caleyachetty, R, et al.
Argitaratua: (2021)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
nork: K. O. Shnaider, et al.
Argitaratua: (2023-12-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
nork: Konstantinos Koskinas, et al.
Argitaratua: (2016-07-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
nork: Christopher LaFratte, et al.
Argitaratua: (2023-09-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
nork: Nissen, SE, et al.
Argitaratua: (2016)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
nork: Mohsin Haseeb, et al.
Argitaratua: (2023-03-01)

JACC: Asia
nork: Jian'an Wang, MD, PhD
Argitaratua: (2021-06-01)

JACC: Asia
nork: Valentin Fuster, MD, PhD, et al.
Argitaratua: (2021-06-01)

The PCSK9 decade
nork: Gilles Lambert, et al.
Argitaratua: (2012-12-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
nork: Mbikay Majambu, et al.
Argitaratua: (2008-06-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
nork: Shuai Wang, et al.
Argitaratua: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
nork: Ying Xiao, et al.
Argitaratua: (2022-11-01)

PCSK9 inhibitors
nork: Baris Gencer, et al.
Argitaratua: (2015-04-01)

JACC: Case Reports
nork: Julia Grapsa, MD, PhD, et al.
Argitaratua: (2019-08-01)

JACC: Case Reports
nork: Julia Grapsa, MD, PhD, et al.
Argitaratua: (2020-06-01)

JACC: Case Reports
nork: Purvi Parwani, MBBS, MPH, et al.
Argitaratua: (2020-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
nork: Preiss, D, et al.
Argitaratua: (2016)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
nork: Maram H. Abduljabbar
Argitaratua: (2024-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
nork: Sliz, E, et al.
Argitaratua: (2018)

Vision for JACC: Case Reports
nork: Julia Grapsa, MD, PhD
Argitaratua: (2019-06-01)

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week
nork: Armitage, J, et al.
Argitaratua: (2019)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
nork: A. V. Blokhina, et al.
Argitaratua: (2022-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
nork: Markus Mohaupt
Argitaratua: (2016-07-01)

PCSK9 Inhibitors: The Evolving Future
nork: Bijay Mukesh Jeswani, et al.
Argitaratua: (2024-11-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
nork: Naoto Kuyama, et al.
Argitaratua: (2021-06-01)

Introducing JACC: Basic to Translational Science
nork: Douglas L. Mann, MD, et al.
Argitaratua: (2016-01-01)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
nork: Weiqi Zeng, et al.
Argitaratua: (2023-08-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
nork: Preiss, D, et al.
Argitaratua: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
nork: Dennis T. Ko, et al.
Argitaratua: (2018-11-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
nork: Tiny Nair
Argitaratua: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
nork: Martin Jozef Péč, et al.
Argitaratua: (2023-08-01)

A Comprehensive Review of PCSK9 Inhibitors
nork: Caroline Coppinger BS, et al.
Argitaratua: (2022-05-01)

Cholesterol and stroke: role of PCSK9 inhibitors
nork: L. Castilla-Guerra, et al.
Argitaratua: (2019-04-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
nork: A. Yu. Filatova, et al.
Argitaratua: (2019-06-01)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
nork: Marianna Puccini, et al.
Argitaratua: (2022-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
nork: Blom DJ, et al.
Argitaratua: (2016-05-01)

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
nork: Zinan ZHAO, et al.
Argitaratua: (2020-10-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
nork: Lillian Smith, et al.
Argitaratua: (2016-03-01)